Brought to you by:
Pioneering Florida limb preservation program laser-focuses on evidence-based, customized care for PAD
This advertorial is sponsored by Tampa General Hospital. As the prevalence of peripheral arterial disease (PAD) continues to climb across the U.S. and globally, a pioneering limb preservation program in south Florida is sharpening its resolve to provide cutting-edge treatment…
New analysis: Four multicenter trials support primary use of drug-coated balloons over bare metal stents in femoropopliteal lesions
A patient-level, propensity-adjusted comparison of three-year results from a quartet of prospective, multicenter trials support the primary use of drug-coated balloons (DCBs) versus bare metal stents (BMS) in moderately complex femoropopliteal lesions, new data show. Lead researcher Mehdi Shishehbor, DO,…
Selution SLR receives second FDA IDE approval
Selution SLR, MedAlliance’s sirolimus-eluting balloon, has received conditional Food and Drug Administration (FDA) investigational device exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of occlusive disease of the superficial femoral artery (SFA). This comes only a…
Tissue samples show paclitaxel effect in minority of CLTI patients receiving DCB angioplasty, study finds
Paclitaxel effect was witnessed in tissue specimens of a minority of chronic limb-threatening ischemia (CLTI) patients treated with drug-coated balloons (DCBs)—but was not dependent on DCB type, nor the dose level of the drug administered, and was not associated with…
CX 2022: IN.PACT AV DCB shows sustained and superior performance compared to PTA through three years
New randomized controlled data demonstrating the sustained and superior performance of IN.PACT AV drug-coated balloons (DCBs) compared to percutaneous transluminal angioplasty (PTA) through 36 months, with no difference in mortality, was revealed during a Podium 1st presentation at the 2022 Charing…
Medtronic issues voluntary recall for subset of IN.PACT Admiral and IN.PACT AV DCBs
Medtronic recently voluntarily recalled a subset of its IN.PACT Admiral and IN.PACT AV paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheters due to the potential for pouch damage resulting in a loss of sterility. This is according to a news alert…
IN.PACT Admiral DCB performs well across wide range of clinical, anatomical scenarios in pooled analysis
In a pooled analysis of the predictors of drug-coated balloon (DCB) effectiveness, the IN.PACT Admiral DCB (Medtronic) performed well across a broad range of clinical, anatomical and procedural scenarios. This is according to Prakash Krishnan, MD, an interventional cardiologist at Mount Sinai…
The top 10 most popular Vascular Specialist stories in September
Five-year data from the ACST-2 trial comparing carotid endarterectomy and carotid artery stenting, a report from the Crawford Forum at the 2021 Vascular Annual Meeting (VAM), and an Eastern Vascular Society (EVS) annual meeting piece reporting on vascular surgery as…
IN.PACT AV DCB sustained ‘superior’ effectiveness in subgroups with high reintervention rates out to two years
Several subgroups of patients treated with the IN.PACT AV drug-coated balloon (DCB) for arteriovenous fistulas (AVFs) demonstrated a “statistically significant” higher rate of target lesion primary patency (TLPP) compared to those who underwent standard percutaneous transluminal angioplasty (PTA) through 24…
Two-year Ranger DCB data demonstrate ‘sustained, high rate’ of device efficacy
Patients treated with Boston Scientific’s Ranger drug-coated balloon (DCB) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year results from the RANGER II SFA randomized controlled trial have demonstrated, investigators revealed during a late-breaking session…